Shekher Bose: Asundexian’s Targeted Factor XIa Inhibition May Transform Secondary Stroke Prevention Strategies
Shekher Bose, Client Partner at Beyondsight Intelligence, reposted Beyondsight Intelligence’s post on LinkedIn, adding:
”Asundexian’s targeted Factor XIa inhibition offers potent antithrombotic protection with a differentiated safety profile (minimal impact on hemostasis), potentially transforming care for millions worldwide and could pave the way for broader, safer secondary stroke prevention strategies—if approved.”
Quoting Beyondsight Intelligence‘s post:
”Bayer’s Asundexian Cuts Stroke Risk by 26%, No increase in major bleeding in Phase 3
Bayer reported positive topline results from the Phase 3 OCEANIC-STROKE trial evaluating asundexian (50 mg), an investigational once-daily oral Factor XIa inhibitor.
Key Highlights:
• 26% reduction in recurrent stroke risk vs placebo
• Studied in patients with prior non-cardioembolic ischemic stroke or high-risk TIA
• Added on top of standard antiplatelet therapy
• No increase in ISTH major bleeding vs placebo
• Designed for effective thrombosis prevention with a wider safety margin
Why It Matters:
• Current antithrombotics often require a trade-off between efficacy and bleeding risk
• Factor XI inhibition is emerging as a next-generation anticoagulation strategy
• Could enable safer long-term secondary stroke prevention
Key Takeaway:
Asundexian’s Phase 3 results suggest meaningful stroke risk reduction without the usual bleeding penalty—potentially reshaping the future of antithrombotic therapy.
Follow our page for more such updates.
News Source Demonstrated a Substantial Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack With No Increase in ISTH Major Bleeding Versus Placebo”
Stay updated with Hemostasis Today.
-
Sep 4, 2026, 05:38Faizan Khan: Why Common Exposures Matter in VTE Risk
-
Sep 4, 2026, 04:56Marwa Mostafa: Microcytosis Is Not Always Iron Deficiency
-
Sep 4, 2026, 03:18Mukesh Kumar Maurya: Beyond ‘aPL Thrombosis’ – A Modern Approach to APS
-
Sep 4, 2026, 02:44Ahmed Kotb: Emergency Management of Critical Bleeding in ITP
-
Sep 4, 2026, 02:30Mario Jimenez: KDIGO 2026 – A More Proactive Approach to IV Iron in Hemodialysis
-
Sep 4, 2026, 02:18Edgardo Alania: Edoxaban in Intracranial Haemorrhage Survivors with AF
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community